Up 44% Since IPO: Why a Major Fund Just Made a $45 Million Bet on This Digital Health Stock

Source Motley_fool

Key Points

  • Connecticut-based fund Braidwell initiated a position in HNGE last quarter, adding 910,476 shares worth an estimated $44.7 million.

  • The transaction represents 1.81% of Braidwell's reportable AUM.

  • The new position remains outside the fund’s top five holdings.

  • These 10 stocks could mint the next wave of millionaires ›

Connecticut-based fund Braidwell initiated a new stake in Hinge Health (NYSE:HNGE), adding 910,476 shares during the third quarter, an estimated $44.7 million position, according to a November 14 SEC filing.

What Happened

According to a Securities and Exchange Commission (SEC) filing published November 14, Braidwell established a new position in Hinge Health (NYSE:HNGE), acquiring 910,476 shares during the third quarter. The estimated value of the stake is $44.7 million based on the quarter-end price. Hinge Health did not appear in the fund’s previous quarterly disclosure.

What Else to Know

The new position in Hinge Health accounts for 1.8% of Braidwell's $2.5 billion in reportable U.S. equity assets under management as of September 30.

Top holdings after the filing:

  • NASDAQ:CAI: $221.3 million (9% of AUM)
  • NASDAQ:XENE: $144.7 million (5.9% of AUM)
  • NASDAQ:CGON: $132.3 million (5.4% of AUM)
  • NASDAQ:NBIX: $123.6 million (5% of AUM)
  • NASDAQ:KRYS: $91.9 million (3.7% of AUM)

As of Wednesday, shares of Hinge Health were priced at $46.02, up 43% since their IPO price of $32 in May and well outperforming the S&P 500, which is up 13%.

Company Overview

MetricValue
Price (as of Wednesday)$46.02
Market capitalization$3.6 billion
Revenue (TTM)$534.4 million
Net income (TTM)($533.2 million)

Company Snapshot

  • Hinge Health offers a digital health platform focused on musculoskeletal care, including solutions for joint and muscle health, acute injury management, chronic pain, and post-surgical rehabilitation.
  • The company operates a software-as-a-service (SaaS) business model, providing digital health solutions to clients on a subscription basis.
  • It serves large employers, health insurers, and healthcare providers seeking to improve outcomes and reduce costs for musculoskeletal conditions.

Hinge Health, Inc. is a healthcare technology company specializing in digital solutions for musculoskeletal health, leveraging a scalable software platform to address chronic pain and rehabilitation needs. The company operates at significant scale, with its enterprise-focused approach and integration with employer and insurer health programs underpin its competitive differentiation in the healthcare technology landscape.

Foolish Take

A big fund stepping into a newly public name this early often signals conviction not just in momentum, but in the underlying economics—and Hinge Health’s latest results give long-term investors a clearer picture of what that bet is tied to. The company is scaling rapidly: Third-quarter revenue jumped 53% year-over-year to $154.2 million, while GAAP gross margin expanded to 82% and free cash flow hit a record $81.3 million. With more than 1.5 million lifetime members and a 25% increase in clients to 2,560, Hinge is demonstrating the operating leverage and sticky enterprise relationships investors typically look for in digital health platforms.

For Braidwell, a new SaaS-heavy healthcare name fits neatly alongside its broader thesis of backing scaled, high-need solutions. The 1.8% allocation is small relative to top positions but aligns with its pattern of building early stakes in companies showing accelerating fundamentals.

Long-term investors should watch whether Hinge can sustain margin expansion as it continues investing in AI-powered care delivery. Updated guidance—calling for full-year revenue growth of 47% and non-GAAP operating income of $106 million to 108 million—adds support to the growth narrative, but valuation and competition in employer-focused digital health remain among the most important risks.

Glossary

Stake: The ownership interest or investment a person or entity holds in a company.
Assets under management (AUM): The total market value of investments that a fund or manager oversees on behalf of clients.
Reportable AUM: The portion of a fund’s assets that must be disclosed in regulatory filings.
Position: The amount of a particular security or investment held by an investor or fund.
Quarterly disclosure: A report funds must file every three months, detailing their investment holdings.
Top holdings: The largest investments in a fund’s portfolio, usually ranked by market value.
Alpha: A measure of an investment’s performance compared to a benchmark, indicating value added or subtracted by active management.
Musculoskeletal care: Medical treatment and management of bones, muscles, joints, and related conditions.
Employer and insurer health programs: Health benefit plans provided by companies or insurance firms to cover employees or members.
Third quarter: The three-month period from July 1 to September 30 in a company’s financial year.
Digital health platform: Technology-based services that deliver healthcare solutions, often remotely or via software.
TTM: The 12-month period ending with the most recent quarterly report.
Software-as-a-service (SaaS): A business model in which software is licensed on a subscription basis and is centrally hosted.

Where to invest $1,000 right now

When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor’s total average return is 1,018%* — a market-crushing outperformance compared to 194% for the S&P 500.

They just revealed what they believe are the 10 best stocks for investors to buy right now, available when you join Stock Advisor.

See the stocks »

*Stock Advisor returns as of December 1, 2025

Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Krystal Biotech. The Motley Fool recommends Neurocrine Biosciences. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
US Dollar's Decline Predicted in 2026: Morgan Stanley's Outlook on Currency VolatilityMorgan Stanley forecasts a 5% drop in the dollar by mid-2026, attributed to continued Fed rate cuts. A recovery may follow as growth improves and funding currency dynamics shift favorably toward the euro and Swiss franc.
Author  Mitrade
Nov 25, Tue
Morgan Stanley forecasts a 5% drop in the dollar by mid-2026, attributed to continued Fed rate cuts. A recovery may follow as growth improves and funding currency dynamics shift favorably toward the euro and Swiss franc.
placeholder
Silver Extends Record Rally on Supply Squeeze and Rate-Cut BetsSilver surged to a new high on Monday, extending a record-breaking rally as traders bet on persistent supply tightness and rising expectations for U.S. interest-rate cuts. Gold held steady.
Author  Mitrade
Dec 01, Mon
Silver surged to a new high on Monday, extending a record-breaking rally as traders bet on persistent supply tightness and rising expectations for U.S. interest-rate cuts. Gold held steady.
placeholder
U.S. Dollar Weakened by Dismal Manufacturing Data; Rate Cut Expected This MonthThe U.S. dollar remains under pressure as disappointing manufacturing data heightens expectations for a rate cut by the Federal Reserve at its upcoming meeting on December 10. Manufacturing PMI fell to 48.2, marking the ninth consecutive month of contraction.
Author  Mitrade
Dec 02, Tue
The U.S. dollar remains under pressure as disappointing manufacturing data heightens expectations for a rate cut by the Federal Reserve at its upcoming meeting on December 10. Manufacturing PMI fell to 48.2, marking the ninth consecutive month of contraction.
placeholder
Asian Shares Rebound as Wall Street Gains and Fed Rate Cut Anticipation LoomsAsian markets stabilized thanks to Wall Street's recovery, with Bitcoin regaining $90,000. Investor focus shifts to a potential Federal Reserve rate cut, improving overall market sentiment ahead of December.
Author  Mitrade
23 hours ago
Asian markets stabilized thanks to Wall Street's recovery, with Bitcoin regaining $90,000. Investor focus shifts to a potential Federal Reserve rate cut, improving overall market sentiment ahead of December.
placeholder
Silver Pulls Back From Record High as Investors Await US Economic DataSilver prices fell on Wednesday, retreating from the previous session’s all-time peak, as traders turned cautious ahead of key U.S. economic reports that could influence the Federal Reserve’s policy path.
Author  Mitrade
17 hours ago
Silver prices fell on Wednesday, retreating from the previous session’s all-time peak, as traders turned cautious ahead of key U.S. economic reports that could influence the Federal Reserve’s policy path.
goTop
quote